Potent and selective Cdc7 inhibitor (IC50
= 3.4 nM). Exhibits >12-fold selectivity for Cdc7 over PIM-1 kinase and >30-fold selectivity over pMCM and CK2. Inhibits proliferation of Colo 205 cells in vitro
and attenuates tumor growth of Colo 205 xenografts in mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
Sasi et al.
PLoS ONE, 2014;9:e113300
Discovery of XL413, a potent and selective CDC7 inhibitor.
Koltun et al.